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ABSTRACT
Ghrelin system comprises a complex family of peptides, receptors (GHSRs), 
and modifying enzymes [e.g. ghrelin-O-acyl-transferase (GOAT)] that control 
multiple pathophysiological processes. Aberrant alternative splicing is an emerging 
cancer hallmark that generates altered proteins with tumorigenic capacity. Indeed, 
In1-ghrelin and truncated-GHSR1b splicing variants can promote development/
progression of certain endocrine-related cancers. Here, we determined the 
expression levels of key ghrelin system components in neuroendocrine tumor 
(NETs) and explored their potential functional role. Twenty-six patients with 
NETs were prospectively/retrospectively studied [72 samples from primary and 
metastatic tissues (30 normal/42 tumors)] and clinical data were obtained. The 
role of In1-ghrelin in aggressiveness was studied in vitro using NET cell lines 
(BON-1/QGP-1). In1-ghrelin, GOAT and GHSR1a/1b expression levels were 
elevated in tumoral compared to normal/adjacent tissues. Moreover, In1-ghrelin, 
GOAT, and GHSR1b expression levels were positively correlated within tumoral, but 
not within normal/adjacent samples, and were higher in patients with progressive 
vs. with stable/cured disease. Finally, In1-ghrelin increased aggressiveness 
(e.g. proliferation/migration) of NET cells. Altogether, our data strongly suggests a 
potential implication of ghrelin system in the pathogenesis and/or clinical outcome of 
NETs, and warrant further studies on their possible value for the future development 
of molecular biomarkers with diagnostic/prognostic/therapeutic value.
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INTRODUCTION
Neuroendocrine tumors (NETs) comprise a 
heterogeneous group of relatively rare neoplasias with 
a primary site originated in the gastrointestinal tract, the 
pancreas and the lung [1]. Although NETs were initially 
thought to be uncommon, the incidence and prevalence 
of these tumors are increasing at a rate of 3–10% per year 
[2, 3]. Gastro-entero-pancreatic NETs (GEP-NETs) are the 
most common type of tumors, and have been classified 
by the World Health Organization into three categories 
(G1, G2 and G3) based on tumor size, histopathological 
differentiation, proliferation index (Ki-67), hormonal 
behavior, neuroendocrine biomarkers (such as serotonin 
and chromogranin A), direct invasion, and distant 
metastasis [4–6]. Although this classification is useful to 
predict prognosis and postoperative recurrence, diagnosis 
of NETs is frequently delayed several years, probably 
due to the rare and heterogeneous nature of NETs and the 
nonspecific initial symptoms. As a result, patients are often 
diagnosed at advanced stages, when cure is no longer 
possible, which leads to worsening the patient’s quality of 
life, and to an increase in health care costs [2, 3]. Indeed, 
despite their identification more than a century ago, NETs 
remain a poorly understood disease from the clinical and 
molecular point of view. Accordingly, identification of new 
molecular diagnostic/prognostic markers, to better define 
their tumor behavior, from proliferation and metastasis to 
secretory mechanisms, deem necessary to provide clues 
for novel therapeutic targets [7, 8].
The ghrelin system is a multifunctional regulatory 
complex composed of several peptides derived from 
the ghrelin gene, their known and —expectably— still 
unknown receptors, and modifying enzymes. This 
system is widely distributed throughout a variety of 
tissues, including the gastrointestinal tract (GIT) and the 
lung, where it can exert a plethora of physiological and 
pathological actions, including the control of hormonal 
secretions, energy homeostasis, inflammatory processes, 
and tumor development and progression [9, 10]. The first 
peptide identified among the ghrelin gene products was 
native (canonical) ghrelin, a 28 amino acid (aa) hormone 
that can be found in acylated (AG; modified with an 
octanoyl group in the Ser-3) and unacylated forms. AG 
is the peptide able to bind and activate the only known 
ghrelin receptor (GHSR1a), which belongs to the family 
of G-protein-coupled receptors with seven transmembrane 
domains [9, 11]. The enzyme responsible for ghrelin 
acylation belongs to the super-family of membrane bound 
O-acyltransferases (MBOAT) and is termed MBOAT4 or, 
commonly, ghrelin-O-acyl-transferase (GOAT) [12, 13]. 
Soon after the discovery of native ghrelin, a number of 
alternative ghrelin gene-derived peptides and mRNA 
splice variants were identified [9, 14]. One of these splice 
forms, the In1-ghrelin variant, is also expressed in the 
GIT and pancreas [15, 16]. In1-ghrelin peptide shares the 
initial 13 aa with native ghrelin, including the first 5-aa, 
which is the minimum sequence required for ghrelin 
acylation by GOAT and for binding and activation 
of GHSR1a [9, 15]. However, the aa sequence of the 
C-terminal tail of In1-ghrelin is totally altered due to the 
retention of intron 1. Interestingly, not only the ghrelin 
gene, but also the ghrelin receptor gene can undergo 
additional processes of alternative splicing to generate 
the GHSR1b spliced variant which, as the In1-ghrelin 
variant, also results from retention of an intron generating 
a truncated G-protein-coupled receptor isoform, with only 
five transmembrane domains, whose functional activities 
remain to be fully elucidated [9, 17].
There is growing evidence indicating that changes 
in the expression of specific components of this system 
can be associated to the development and/or progression 
of various cancers. Specifically, several studies have 
demonstrated that key components of the ghrelin system 
(e.g. native ghrelin, GHSR1a and GHSR1b) are expressed 
in various tumors including pituitary adenomas and breast 
and prostate cancer, thus suggesting a possible autocrine 
or paracrine role of ghrelin system in the pathogenesis 
of these tumors (for review see: [9]). In fact, our group 
recently described that the In1-ghrelin spliced variant 
could contribute to the pathogenesis of breast tumors and 
pituitary adenomas [13, 16]. However, there is still limited 
and conflicting data available on the precise functional 
roles that play the different components of the ghrelin 
system in the patho-physiology of cancer development 
and progression. Moreover, to the best of our knowledge, 
there is only limited, descriptive evidence on the presence 
of some components of the ghrelin system in NETs 
[9, 18, 19], but their exact role, relevance and implication 
with the development and/or progression of NETs has not 
been explored in detail.
In this study, we sought to analyze systematically 
the presence of different components of the ghrelin system 
(native-ghrelin, GOAT and GHRS1a) and its key splice 
variants (In1-ghrelin and GHSR1b) in human NETs and, 
compared their expression with the corresponding adjacent 
non-tumoral tissues. Additionally, we aimed to evaluate 
the functional role of In1-ghrelin variant on proliferation, 
migration, serotonin secretion and expression of 
proliferative and apoptotic markers in NET cell lines 
(BON-1 and QGP-1). Results from our study strongly 
suggest a potential role for the ghrelin system, particularly 
In1-ghrelin and GHSR1b, in NET pathophysiology.
RESULTS
A total of 26 patients with GEP-NETs (mean age 
58.3 ± 14.4 years old; 57.7% women) were included in 
the study. Patients’ clinical and pathological features 
are summarized in Table 1. Thirteen patients (50%) had 
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pancreatic tumors (7 non-functional, 5 insulinomas and 
1 ectopic Cushing’s) and the rest had gastrointestinal 
carcinoid tumors. Fifteen patients (58%) presented 
with metastases, the majority of them in regional 
lymph nodes and/or liver. Pre-surgical chromogranin 
A was determined in 22 patients, with a mean value 
of 19.7 ± 21.2 ng/ml [median 15.3 (0–77) ng/ml]. 
Immunoperoxidase staining for chromogranin A and 
synaptophysin was positive in all tumor tissues. A Ki-67 
immunoreactivity level >2% was observed in 7 out of the 
14 available samples [mean Ki-67 index 10.7 ± 23.3%; 
median 2.5 (2–90) %].
Ghrelin system components are overexpressed in 
GEP-NETs in comparison to normal tissues
qPCR analysis performed in GEP-NET tissue 
samples revealed that native ghrelin was expressed in 
35.7% (n = 15/42), its cognate GHSR1a receptor in 88.1% 
(n = 37/42) and GOAT in 85.7% (n = 36/42) (Table 2). 
Interestingly, we found a high expression of the splicing 
variants of the ghrelin system in GEP-NETs. Specifically, 
the In1-ghrelin variant was expressed in more GEP-NET 
samples than native ghrelin [81% (n = 34/42) vs. 35.7% 
(n = 15/42); mean mRNA copy number: 0.038 ± 0.007 
Table 1: General characteristics of the patient population and samples
Patient Baseline characteristic (n = 26)
Gender
Male 11 (42.3%)
Female 15 (57.7%)
Age, years
< 55 11 (42,3%)
≥ 55 15 (57,7%)
Stage (ENETS)
I 6 (26.1%)
II 5 (19,2%)
III 2 (7.7%)
IV 13 (50%)
Sample characteristics (n = 72)
Sample type
Primary tumor tissue 26 (36.1%)
Metastatic tissue 16 (22,2%)
Non-tumor adjacent tissues 30 (41,7%)
Primary site
Pancreatic neuroendocrine tumor 13 (50%)
Carcinoid gastrointestinal NET 13 (50%)
Primary tumor size, cm
< 3.0 16 (62.5%)
≥ 3,0 10 (38.5%)
Grading (WHO 2010 criteria)
Low 7 (26.9%)
Intermediate 6 (26.1%)
High 1 (3.8%)
Unknown 12 (46.2%)
Abbreviations: NET = Neuroendocrine tumor; WHO = World Health Organization; GOAT = Ghrelin O-acyltransferase.
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vs. 0.00283 ± 0.00025, respectively; 13-fold higher, 
(p < 0.001; Table 2). Similarly, although truncated 
GHSR1b variant was expressed in a similar percentage 
of GEP-NET tissues as GHSR1a [92.9% (n = 39/42) 
vs. 88.1% (n = 37/42)], the expression levels of this 
spliced receptor variant were significantly higher than the 
expression of GHSR1a in GEP-NETs (mean mRNA copy 
number: 1.764 ± 0.400 vs. 0.215 ± 0.098, respectively; 
8-fold higher, (p < 0.001; Table 2).
We observed a striking dysregulation of the 
expression patterns of several components of the ghrelin 
system in GEP-NETs in comparison to non-tumor adjacent 
tissues. Specifically, whereas mean mRNA levels of 
native ghrelin were not different between tumoral and 
non-tumoral adjacent samples (Figure 1A), we found 
that mean expression levels of GHSR1a, GOAT, and also 
of the splice variants In1-ghrelin and GHSR1b, were 
significantly increased in GEP-NET tissues compared 
to the non-tumoral adjacent regions (Figure 1A). 
Interestingly, mRNA expression levels of In1-ghrelin 
strongly correlated with those of GOAT in GEP-NETs 
(Figure 1B). This finding was not observed, however, 
for native ghrelin. In addition, whereas GHSR1a mRNA 
levels did not correlate with native ghrelin or In1-ghrelin 
levels, we found that expression levels of GHSR1b 
paralleled those of In1-ghrelin. However, once again, 
this was not observed for native ghrelin (Figure 1C). 
Furthermore, GHSR1b and GOAT expression levels were 
positively correlated in tumors (Figure 1D).
Further sub-analyses of the expression of the ghrelin 
components according to tumor site (primary or metastatic 
tissues) showed a consistent increase of In1-ghrelin 
as well as of the two ghrelin receptors (GHSR1a and 
GHSR1b) in both categories, while GOAT and native 
ghrelin expression levels were elevated only in metastatic 
tissues (Supplemental Figure 1).
In1-ghrelin, GOAT and GHSR1b expression is 
associated to worse patient outcome
Patients were grouped into three categories 
according to their clinical outcome (complete tumor 
remission, stable disease or progressive disease), and the 
relevance of the increased expression levels observed 
for some of the components of the ghrelin system was 
evaluated accordingly. No significant differences were 
found in mean expression levels of native ghrelin and 
GHSR1a between the three groups (Figure 2A). In 
contrast, higher mRNA levels of GOAT, In1-ghrelin and 
GHSR1b were associated to a worse clinical outcome 
(Kruskall-Wallis one-way ANOVA test: p = 0.014, 
p = 0.004 and p = 0.014, respectively; Figure 2A). These 
differences were particularly noticeable when comparing 
tumor samples from patients with complete remission 
and those with progressive disease (by Dunn’s multiple 
comparisons test: p < 0.05, p < 0.01 and p < 0.05; or 
by Student’s t-test: p < 0.01, p < 0.001 and p < 0.05, 
respectively; Figure 2A). In fact, ROC analysis of all the 
components of the ghrelin system showed that expression 
of GOAT, GHSR1b, and, specially, In1-ghrelin, 
discriminated between categories of clinical outcome 
(Figure 2B). Conversely, native ghrelin and GHSR1a 
expression showed a poor ability to distinguish between 
the two diagnostic groups (ROC curves similar to the 
reference line; data not shown). Importantly, as illustrated 
in Figures 2A and 2B, expression of the In1-ghrelin variant 
was the best and most accurate marker to distinguish 
between patients presenting complete disease remission or 
progressive disease. Furthermore, In1-ghrelin expression 
levels, but not those of GOAT or GHSR1b, were also 
significantly higher in tumor samples from patients with 
stable disease, compared to those with complete disease 
remission (p < 0.05 by Student’s t-test; Figure 2A). 
Taken together, these findings invite to hypothesize that 
In1-ghrelin could serve as a potential new molecular 
diagnostic/prognostic marker and/or a tool to identify new 
therapeutic targets for the treatment of GEP-NETs and, 
hence, should be explored further.
Expression of the splice variants of the ghrelin 
system, especially In1-ghrelin, is associated 
with features of malignancy in patients with 
GEP-NETs
Clinical outcome of patients with GEP-NETs is 
believed to depend on the aggressiveness of the tumor 
itself. Therefore, we explored the putative associations 
between the expression levels of the ghrelin system 
Table 2: Percentage (%) of control normal-adjacent tissues and NET tissues expressing the 
components of the ghrelin system and mean mRNA copy number of each component ± SEM 
(adjusted by β-actin expression)
GOAT Ghrelin In1-ghrelin GHSR1a GHSR1b
Control 22/30 (73.3%) 6/30 (20.0%) 15/30 (50.0%) 8/25 (32.0%) 21/30 (70.0%)
0.259 ± 0.077 0.003 ± 0.002 0.008 ± 0.003 0.093 ± 0.063 0.409 ± 0.111
Tumor 36/42 (85.7%) 15/42 (35.7%) 34/42 (80.9%) 37/42 (88.1%) 39/42 (92.9%)
0.3499 ± 0.055 0.0028 ± 0.002 0.0384 ± 0.007 0.2158 ± 0.097 1.764 ± 0.400
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Figure 1: Expression of ghrelin system components in NETs. A. The mRNA expression levels of the ghrelin system 
components (ghrelin, In1-ghrelin, GOAT, GHSR1a and GHSR1b) were determined by qPCR in a battery of NETs and compared to 
their adjacent non-tumoral control tissues. B. Correlation between ghrelin or In1-ghrelin levels and GOAT expression levels in NET 
samples. Correlation between ghrelin or In1-ghrelin levels and GHSR1a C. or GHSR1b D. expression levels in NET samples. Data represent 
mean ± SEM. Asterisks (*p < 0.05; ***p < 0.001) indicate values that significantly differ from the adjacent non-tumoral control tissues.
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components in GEP-NET tumor samples and the 
corresponding clinical, anatomical and pathological 
characteristics of patients. In this regard, we evaluated 
expression levels in primary tumors of patients who 
developed metastases, compared to those who did not. 
Interestingly, we found that only the expression levels 
of the spliced variants of the ghrelin system, In1-ghrelin 
and GHSR1b, were significantly elevated in the primary 
Figure 2: Expression of ghrelin system components in the tumoral samples of patients with different outcome. A. The 
mRNA expression levels of the ghrelin system components (ghrelin, In1-ghrelin, GOAT, GHSR1a and GHSR1b) determined by qPCR 
in the tumoral samples were classified depending on the outcome of the patient (complete remission, stable disease or progression of 
the tumor). B. Receiver operating characteristic (ROC) curve analysis to determine the accuracy of ghrelin system components (GOAT,  
In1-ghrelin and GHSR1b) as diagnostic test to discriminate between NETs with complete remission or progressive disease [the closer the 
ROC curve is to the upper left corner of the graphic (i.e., higher sensitivity and specificity), the higher the overall accuracy of the marker 
used]. Data represent mean ± SEM. Asterisks (*p < 0.05; **p < 0.01; ***p < 0.001) indicate values that significantly differ from the NETs 
with complete remission.
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tumors of patients that developed metastasis, as compared 
to those that did not (Figure 3A). In fact, although similar, 
but not statistically significant, trends were observed 
for GHSR1a and GOAT expression (Figure 3A), ROC 
analysis of all these components confirmed that only the 
expression of In1-ghrelin and GHSR1b splicing variants 
could discriminate between these two diagnostic groups 
(development of metastasis vs. no metastases; Figure 3B).
Because expression of the In1-ghrelin variant was 
consistently elevated in all GEP-NET types (primary and 
metastasis tissues), and that it was associated to expression 
levels of GOAT and GHSR1b in GEP-NET tissues, we 
deemed of great interest to explore the putative role of this 
novel In1-ghrelin variant in the pathophysiology of these 
tumors, especially given the fact that this was not observed 
for native ghrelin.
Overexpression of In1-ghrelin is associated with 
increasing features of aggressiveness in human 
NET cells
To examine the possible functional effects of the 
In1-ghrelin variant on NET cells malignancy features, 
we used two commonly accepted models for NET cell 
studies: BON-1 and QGP-1 cell lines (Figure 4). qPCR 
analysis performed in both cell lines revealed that 
the majority of the components of the ghrelin system 
were expressed, at different levels, except for GHSR1a 
(i.e. its expression was under the detection limit) 
(Figure 4A and 4B). In particular, In1-ghrelin was the 
ghrelin system component most abundantly expressed 
in QGP-1 cells, followed by native ghrelin and GOAT, 
and by a modestly expressed GHSR1b (Figure 4A). 
Figure 3: Expression of ghrelin system components in primary NETs with or without metastasis. A. The mRNA expression 
levels of the ghrelin system components (ghrelin, In1-ghrelin, GOAT, GHSR1a and GHSR1b) determined by qPCR in the tumoral samples 
were classified depending on the presence or absence of metastasis. B. Receiver operating characteristic (ROC) curve analysis to determine 
the accuracy of ghrelin system components (In1-ghrelin and GHSR1b) as diagnostic test to discriminate between the metastatic capacities 
of the NETs. Data represent mean ± SEM. Asterisks (*p < 0.05) indicate values that significantly differ from the NETs without metastasis.
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Conversely, native ghrelin and GOAT were the most 
predominantly expressed components of the ghrelin 
system in BON-1 cells, followed by In1-ghrelin 
expression, and by a much lower GHSR1b expression 
level (Figure 4B).
We then overexpressed In1-ghrelin in both cell 
lines by transfection with a specific expression vector 
containing the appropriate coding region of the In1-
ghrelin variant. We verified an increased number 
of mRNA copies of In1-ghrelin compared to 
mock-transfected controls by qPCR (Figures 4C 
and 4D: first left panels). This strategy revealed 
that In1-ghrelin overexpression increased the 
proliferation rate of BON-1, but not of QGP-1 cells, 
Figure 4: Effects of In1-ghrelin overexpression in NET-derived cell lines. A. Normalized levels of ghrelin system 
components (ghrelin, In1-ghrelin, GOAT, GHSR1a and GHSR1b) in QGP-1 NET cell lines and B. BON-1 NET cell lines. Functional 
assays in In1-ghrelin transfected QGP-1 cell lines C. and BON-1 cell lines D. compared to mock control cells. Panel order from left to right: 
In1-ghrelin overexpression; proliferation rate; Ki67 expression; migration capacity; and serotonin secretion. Data represent mean ± SEM 
of n = 3 − 6 independent experiments. Asterisks (*p < 0.05; **p < 0.01) indicate values that significantly differ from mock control cells.
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compared to their corresponding mock-transfected 
control cells (Figures 4D and 4C, respectively: second 
panels). In agreement with this finding, a significant 
increase in the expression of the proliferation marker 
Ki67 was observed in BON-1, but not in QGP-1, cells 
transfected with In1-ghrelin compared with mock-
transfected cells (Figures 4D and 4C, respectively: third 
panels). Additionally, we also investigated whether 
In1-ghrelin overexpression exerted apoptotic effects 
by measuring the expression levels of two apoptosis-
related markers, TP53 and Bcl2, in both cell lines. Our 
data indicated that overexpression of In1-ghrelin did 
not alter the expression levels of these two apoptosis 
markers in NET cell lines (Supplemental Figure 2), 
suggesting that In1-ghrelin is not involved in the control 
of the expression of these apoptosis-related marker.
Interestingly, further functional assays revealed that 
overexpression of In1-ghrelin significantly stimulated the 
migration capacity of both QGP-1 and BON-1 cells, as 
assessed by wound healing technique (Figures 4C and 4D, 
respectively: fourth panels). Furthermore, In1-ghrelin 
overexpression also increased significantly serotonin 
secretion in both cell lines as compared to their 
corresponding mock-transfected control cells (Figures 4C 
and 4D: fifth panels).
DISCUSSION
NETs have been commonly considered a rare and 
heterogeneous group of neoplasms [1]. However, their 
prevalence is higher than previously thought according 
to recent data from the US Surveillance Epidemiology 
and End Results [2]. Although in recent years there has 
been significant progress in NET medical treatment, with 
the emergence of multiple active therapies [20], these 
strategies are still limited and unsatisfactory. Therefore, 
it is crucial to identify new molecular biomarkers for 
these tumors, which would help to refine their diagnosis, 
to better predict their prognosis and tumor behavior, and 
provide tools to develop novel therapeutic targets.
Earlier studies suggested that the ghrelin system, 
which participates in various endocrine-related tumors 
[9, 10, 21], might also play a relevant role in NET 
pathophysiology. Indeed, some of its components have 
been previously detected in normal and tumoral tissues 
of the GIT [9, 22]. Specifically, ghrelin and GHSR1a 
are expressed in gastric [18, 23–25], intestinal [23, 26], 
pancreatic [18, 25, 27] and/or lung [28] NETs, although 
the expression levels and the percentage of tumors 
expressing native-ghrelin or GHSR1a varied substantially 
depending on the tissue analyzed, and on the detection 
method used. Moreover, to date, it is still unclear whether 
the expression profiles of these or other components of 
the ghrelin system are altered in NETs. Actually, to the 
best of our knowledge, the present report provides the 
first systematic analysis of the expression of different 
components of the ghrelin system in human NET tissues 
as compared to their corresponding adjacent non-tumoral 
tissues, and in relation to clinical parameters of the 
patients.
Our results revealed that the expression profile of 
ghrelin system is markedly altered in NETs compared 
with control adjacent tissues, and that this is dependent 
on the specific component examined, and on the 
tumor site analyzed (primary vs. metastatic tissues). 
Specifically, In1-ghrelin, GHSR1a/1b and GOAT, but 
not of native-ghrelin, expression was increased in NETs 
compared with control adjacent tissues, both in primary 
and in metastatic sites. Moreover, expression was higher 
in metastatic tissue when compared to the primary site, 
suggesting that these components might exert a functional 
role in the NETs pathology. Interestingly, results differed 
in the case of GOAT, which was only overexpressed in 
metastatic tissues. Our results further indicate that 
In1-ghrelin is the variant predominantly expressed 
in NET tissues, in terms of number of NET samples 
and expression levels (i.e. 13-fold higher than those of 
native-ghrelin). This observation compares favorably 
with previous reports indicating that In1-ghrelin, but not 
native-ghrelin, expression is consistently increased in other 
endocrine-related tumors compared with normal tissues, 
including human breast [15] and pituitary [21] tumors. 
Hence, it seems reasonable to suggest that overexpression 
of this In1-ghrelin might be a common cellular/molecular 
signature across various endocrine-related tumors.
This study also demonstrates that a high proportion of 
NETs express GOAT, an enzyme that acylates native-
ghrelin, and presumably also In1-ghrelin variant, which is 
an essential step for ghrelin to bind GHSR1a and to exert 
thereby its neuroendocrine activities [12, 13, 21]. The 
remarkable expression of GOAT in NET tissues compared 
with that in adjacent-control tissues, is in accordance 
with recent findings in breast cancer tissues where GOAT 
mRNA was highly expressed compared with control 
tissues [15], like in prostate cancer cell lines compared 
with normal prostate epithelial-derived cell lines [29]. 
Expression of GOAT enzyme, as well as of native-ghrelin 
and In1-ghrelin in NETs, supports the notion that the 
ghrelin axis might exert active autocrine/paracrine roles in 
these tissues. Actually, expression levels of GOAT in NETs 
positively correlated with In1-ghrelin, but not with native 
ghrelin expression, suggesting that In1-ghrelin might be 
the main ghrelin gene variant functionally linked to GOAT 
in these tumors, and reinforcing the idea that an autocrine/
paracrine circuit involving these two components may 
operate in NETs, especially in metastatic tissues, where 
both components were highly expressed compared with 
adjacent-control tissues.
Regarding the expression of receptors, our analyses 
revealed that NETs not only expressed the canonical, 
full length GHSR1a, but also GHSR1b, which is in line 
with previous reports showing that the latter is present 
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in intestinal carcinoids [23] or pancreatic NETs [25]. 
Moreover, our study is the first to demonstrate that 
expression levels of both receptors are significantly 
elevated in NET tissues compared with non-tumoral 
adjacent tissues. Specifically, the splice variant GHRS1b 
was the dominant ghrelin receptor isoform expressed in 
NET tissues, as its mRNA levels were markedly higher 
(8-fold) than those of GHRS1a. This data is reminiscent 
of earlier reports showing that GHSR1b seems to be 
selectively expressed in prostate hyperplasia [30], as 
well as in breast carcinomas [15], where its abundance 
shows a strong correlation with In1-ghrelin expression 
levels. Interestingly, although GHSR1b expression levels 
in NETs were significantly higher than those of GHSR1a, 
both receptors were expressed in a similar percentage 
of tumor tissues, where their expression levels tended 
to correlate (p = 0.06), suggesting a potential functional 
association between both receptors in NETs. Although 
the actual (patho)physiological role of GHSR1b is 
still unknown, it has been reported that GHSR1b can 
heterodimerize with GHSR1a, promoting translocation of 
the receptor complexes, and acting thereby as a dominant-
negative receptor for the canonical signaling functions 
of GHSR1a [31, 32]. In this scenario, it is tempting to 
speculate that the striking change in the mRNA pattern 
of GHSR1a and GHSR1b found in NET tissues (i.e. 
significant high level of GHSR1b relative to GHSR1a) 
may translate into a relevant functional role in this 
pathology (e.g. by disrupting the normal ghrelin/GHSR1a 
signaling). In fact, whereas GHSR1a mRNA levels do 
not correlate with those of native ghrelin or In1-ghrelin 
in NETs, GHSR1b expression levels did parallel those of 
In1-ghrelin (p = 0.002), but not those of native ghrelin. 
This suggests that In1-ghrelin could be a relevant 
ghrelin gene-derived variant functionally linked to other 
components of the ghrelin system [i.e. with GOAT (as 
discussed previously) and GHSR1b] in NETs and, that 
the cellular machinery responsible for the intron retention 
processes is altered [33].
Further support to the notion that the splice 
variants In1-ghrelin and GHSR1b may promote NETs 
pathogenesis derives from three lines of evidence. 
First, from the observation that there is not only 
a quantitative predominance of the expression of 
these splice variants over their respective canonical 
counterparts in NET tissues, but also that the ratios 
between In1-ghrelin/native-ghrelin, and between 
GHSR1b/GHSR1a are augmented in NET tissues 
as compared with that found in adjacent-control tissues 
(~5-fold and 2-fold higher for In1-ghrelin/native-ghrelin 
and GHSR1b/GHSR1a ratio, respectively). The second 
line of support is provided by the direct association of 
In1-ghrelin, GHSR1b and GOAT expression levels —but 
not of native-ghrelin and GHSR1a— with a worse clinical 
outcome, i.e. tumors of patients with progressive disease 
have higher levels of these components vs. patients 
with complete remission of the tumor. These results 
are also consistent with previous reports showing that 
native-ghrelin expression in pancreatic NETs is not 
clinically associated with tumor size, grade or stage [32], 
and with studies showing that plasma native-ghrelin 
concentrations lie within the normal range in patients 
with NETs [34, 40, 41] (native-ghrelin elevation has only 
been reported in three cases of ghrelinomas [41–43]). 
Additionally, we found that only the expression levels of 
In1-ghrelin and GHSR1b were significantly elevated in the 
primary tumors of patients that developed metastasis, as 
compared to those that did not. And thirdly, ROC curve 
analysis indicated that only the expression of In1-ghrelin 
and GHSR1b could discriminate between the different 
diagnostic groups according to follow-up outcome (tumor 
remission, stable disease, or progressive disease) and 
malignancy features (expression in primary tumors of 
patients that developed metastasis compared to those that 
did not develop metastasis), whereas GOAT expression 
could only discriminate between the diagnostic groups 
of clinical outcome of patients. These findings suggest 
a putative utility of these splicing variants as tools to 
identify novel biomarkers to refine diagnosis and predict 
prognosis of NETs, and for the development of new 
therapeutic tools for the management of human NETs.
Based on previous results showing that In1-ghrelin 
variant can promote features of aggressiveness in breast 
cancer [13] and pituitary tumor cells [16], and on 
the results of our study, which demonstrated that the 
expression of the In1-ghrelin variant is a valuable marker 
to classify patients according to prognosis, we further 
explored the functional role of In1-ghrelin in two NET 
cell models. In vitro data revealed that overexpression 
of In1-ghrelin enhanced features of aggressiveness in 
human NET cells (i.e. increased proliferation rate and 
expression of the Ki67, as well as migration capacity 
and serotonin secretion) which demonstrates that this 
splice variant is functionally active in NET cells. These 
results support and extend previous data from our group 
showing that In1-ghrelin influences key, clinically 
relevant processes, such as proliferation or hormone 
secretion in other endocrine-related pathologies as 
breast cancer [15] and pituitary adenomas [21], further 
suggesting that overexpression of In1-ghrelin might be 
a common cellular/molecular signature across different 
endocrine-related tumors that is directly associated to the 
aggressive features of these pathologies.
Altogether, our results indicate that the ghrelin 
system, specially the splicing variants (In1-ghrelin and 
GHSR1b), is dysregulated in human NETs, where they 
may exert a relevant pathophysiological role. Specifically, 
the observations indicating that In1-ghrelin expression 
is correlated with a worse patient’s outcome, increased 
malignancy, and features of aggressiveness in human NET 
cells support the idea that this system could potentiate the 
pathogenesis of NETs, and may provide useful tools to 
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identify new diagnostic/prognostic biomarkers and explore 
novel therapeutic molecular targets in human NETs.
MATERIALS AND METHODS
Study population and samples
We collected data from 26 patients with GEP-NET 
who underwent surgery at our Hospital from 2001 to 2009 
[mean age 58.4 ± 14.4 years, 15 females (57.7%)]. All 
patients were carefully screened for the presence of other 
malignancies, and special attention was paid to exclude 
an association with neurofibromatosis, multiple endocrine 
neoplasia type 1, or Von Hippel-Lindau syndrome. Only 
one patient was carrier of a MEN-1 gene mutation.
We used clinical records to collect full medical 
history of all patients. Subjects were classified 
following ENETS and WHO criteria (tumor site and 
size, angioinvasion, infiltration level, cell proliferation 
index, immunohistochemical phenotype, and metastases) 
[34, 35]. In addition, GEP-NETs were classified according 
to histopathology features as well-differentiated NETs 
(G1), well differentiated neuroendocrine carcinomas (G2) 
and poorly differentiated neuroendocrine carcinomas 
(G3) [5]. Cell proliferation activity was determined by 
count of Ki-67+ cells, as previously reported [34].
Patients were managed following available 
guidelines and recommendations [36]. Surgery was the 
first option of treatment in all cases, and, if residual disease 
was observed, adjuvant treatment with somatostatin 
analogs was prescribed. Patients were grouped into 
three categories according to their follow-up evaluation: 1) 
complete remission, if there was no evidence of tumor 
relapse/recurrence; 2) stable disease, in cases of residual 
but non-progressive tumor burden; and 3) progressive 
disease, if tumor growth or new lesions were detected. 
The Hospital’s Ethics Committee approved the study, 
which was conducted in accordance with the Declaration 
of Helsinki and according to national and international 
guidelines. All patients signed a written informed consent 
before inclusion.
We obtained 72 formalin-fixed paraffin-embedded 
samples from primary and metastatic tissues from the 26 
patients (Table 1). Of these, 30 samples corresponded to 
normal tissues (26 samples from adjacent non-tumoral 
regions and 4 normal control tissues obtained from 
patients that underwent intestinal, pancreatic or hepatic 
resection). The other 42 samples corresponded to 
tissues with pathological diagnosis of NET [26 from 
the primary site (pancreas or GIT) and 16 obtained 
from a metastatic site]. In order to ensure identification 
of representative and relevant areas of tumor and non-
tumor tissues to carry out the RNA isolation of each 
sample, a comprehensive analysis of hematoxylin and 
eosin (H&E) sections was carried out by a pathologist. 
Simultaneously, immunohistochemical staining was 
carried out in paraffin-embedded blocks by the avidin-
biotin peroxidase complex (ABC) method, using an 
anti-human chromogranin A (CgA) antiserum (Biogenex 
Laboratories, San Ramon, CA USA), synaptophysin, and 
proliferation-related Ki-67 antigen (Dako Cytomation 
Denmark A/S, Copenhagen, Denmark); as well as 
glucagon, insulin, somatostatin and gastrin. Then, tumors 
were classified in accordance to current guidelines [5].
RNA isolation, reverse-transcription and 
quantitative real time PCR (qPCR)
Total RNA from formalin fixed paraffin-embedded 
(FFPE) samples was isolated using the RNeasy FFPE 
Kit (Qiagen, Limburg, Netherlands) according to the 
manufacturer’s instructions. Total RNA was also isolated 
from cultured NET cell lines (see below) using TRIzol 
Reagent (Life Technologies, Barcelona, Spain) following 
the manufacturer’s protocol and subsequently treated with 
DNase (Promega, Barcelona, Spain). Quantification of 
the recovered RNA was assessed using NanoDrop2000 
spectrophotometer (Thermo Scientific, Wilmington, 
NC, USA). One microgram of total RNA was retro-
transcribed to cDNA with the First Strand Synthesis kit 
using random hexamer primers (Thermo Scientific). 
cDNAs were amplified with the Brilliant III SYBR 
Green Master Mix (Stratagene, La Jolla, CA, USA) using 
the Stratagene Mx3000p system and specific primers 
for each transcript of interest. Specifically, expression 
levels (absolute mRNA copy number/50ng of sample) of 
native ghrelin, In1-ghrelin, GOAT, GHSR1a, GHSR1b, 
Ki67, TP53 and Bcl2 were measured using previously 
validated primers (Supplemental Table 1 and/or [15, 37]) 
and methods [15, 38]. Briefly, samples derived from 
human NET tissues or NET cell lines were run, in the 
same plate, against a standard curve to estimate mRNA 
copy number (1, 101, 102, 103, 104, 105, and 106 copies of 
synthetic cDNA template for each transcript) and a No-RT 
sample as a negative control. Thermal profile consisted 
of an initial step at 95°C for 3 minutes, followed by 
40 cycles of denaturation (95°C for 20s) and annealing/
elongation (60°C for 20s), and finally, a dissociation cycle 
(melting curve; 55°C to 95°C, increasing 0, 5°C/30 s) to 
verify that only one product was amplified. To control for 
variations in the amount of RNA used and the efficiency 
of the reverse-transcription reaction, the expression level 
(copy-number) of each transcript was adjusted by the 
expression of beta-actin (used as a control), as previously 
reported [39].
Cell cultures
We used two previously validated NET cell 
lines: carcinoid BON-1 cells [40] and somatostatinoma 
derived QGP-1 cells [41]. BON-1 cell line was 
cultured and maintained in Dulbecco’s Modified Eagle 
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Medium (DMEM-F12; Life Technologies, Madrid, 
Spain) complemented with 10% fetal bovine serum 
(FBS; Sigma-Aldrich, Madrid, Spain) and 0.2% antibiotic 
(Gentamicin/Amphotericin B; Life Technologies). 
Meanwhile, QGP-1 was cultured and maintained in RPMI 
1640 (Lonza, Basel, Switzerland), complemented with 
10% FBS, 1% glutamine and 0.2% antibiotic. Both cell 
lines were maintained at 37°C and 5% CO2, under sterile 
conditions.
Stable transfection of In1-ghrelin peptide
BON-1 and QGP-1 cell lines were stably transfected 
with pCDNA3.1 vector containing In1-ghrelin peptide 
(Life Technologies, Madrid, Spain) and selected as 
previously reported [42]. Specifically, NET cell lines 
were seeded in 6-well culture plates and transfected with 
In1-ghrelin or empty (mock) vectors using Lipofectamine 
2000 Transfection Reagent (Life Technologies, Madrid, 
Spain) following manufacturer’s instructions and selected 
from non-transfected cells by treatment with geneticin 
(Life Technologies, Madrid, Spain). Stable transfection of 
In1-ghrelin was always confirmed by qPCR.
Measurements of proliferation
As previously reported [39, 42], cell proliferation 
of cell lines transfected with In1-ghrelin or empty 
(mock) vectors was measured using the alamar-blue 
fluorescent assay (Life Technologies, Madrid, Spain). 
Briefly, transfected cells were seeded in 96-well plates 
at a density of 3000–5000 per well and serum-starved 
for 12 h. Then, after 3 h of incubation with 10% alamar-
blue serum-free medium, basal proliferation rate was 
obtained by measuring the fluorescent signal exciting 
at 560 nm and reading at 590 nm using the FlexStation 
III system (Molecular Devices, Sunnyvale, CA, USA). 
Subsequently, proliferation rate was similarly measured at 
24, 48 and 72 h after the basal proliferation rate evaluation. 
Medium was replaced by fresh medium containing 
FBS immediately after each measurement. Results 
were expressed as percentage referred to control (mock 
transfected cells). In all experiments, cells were seeded 
per quadruplicate and all experiments were performed a 
minimum of four times.
Measurements of migration capacity
The wound healing technique was used to assess 
the ability of mock and In1-ghrelin stably transfected 
NET cell lines to migrate, as previously reported [42]. 
Briefly, cell lines under confluence status and cultured 
in 6-well plates were serum-starved for 24 h to achieve 
cell synchronization, and then the wound was made using 
a 200 μl sterile pipette tip. Wells were rinsed using PBS 
and subsequently, cells were incubated for 24 h in FBS 
supplemented medium. Wound healing was evaluated as 
the area of a rectangle centered in the picture 24 h after the 
wound vs. the area of the rectangle just after the wound 
was performed. To confirm the migration assay, at least 
three experiments were performed in independent days, 
in which three pictures randomly selected were acquired 
along the wound per well.
Measurements of serotonin secretion
Serotonin secretion was measured in mock and 
In1-ghrelin stably transfected NET cell lines using a 
specific commercially available ELISA kit (ALPCO, 
USA). Briefly, cell lines were seeded in 12-well plates 
at 70% confluence in serum-starved medium and 24 h 
later media were collected and stored at −20°C until 
measurements. Results are expressed as percentage of 
serotonin secretion of In1-ghrelin vs. mock-transfected 
cells. At least four experiments were performed in 
independent days, in which cells were plated per 
duplicate.
Statistical analyses and Receiver Operating 
Characteristic (ROC) curve of the expression of 
the ghrelin system in NET tissues
Descriptive results were expressed as mean ± 
standard deviation (SD), mean ± standard error of 
the mean (SEM), or median ± interquartile range, as 
appropriate. Quantitative variables were evaluated 
using Spearman’s bivariate correlations and differences 
between groups were compared using analysis of 
variance (U-Mann Whitney or Kruskal-Wallis ANOVA). 
Comparison between related variables was performed 
using Wilcoxon sum rank test. Samples from all groups 
within an experiment were processed simultaneously. 
P-values were two-sided and statistical significance 
was considered when P < 0.05. Statistical analyses 
were performed using SPSS 20.0 (IBM SPSS Statistics 
Inc., Chicago, IL, USA) and GraphPad 5.0 (GraphPad 
Software, La Jolla, CA, USA).
As previously reported [43], ROC was performed 
for evaluation of diagnostic test sensibility and 
specificity. Specifically, in this study ROC was used as 
a tool to measure how well the expression of each of 
the components of the ghrelin system analyzed could 
distinguish between different diagnostic groups [clinical 
outcome of patients (tumor remission, stable disease or 
progressive disease) and malignancy features (expression 
in primary tumors of patients that developed metastasis 
compared to those that did not develop metastasis)]. 
Statistical analysis of ROC curves was performed by 
calculating the Area under the Curve (AUC) of each 
transcript and comparing them with the AUC of the 
reference line using Student’s t-test.
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